secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2024-06-28T23:59:59+00:00
Accession:  0001193125-24-171204
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CHMP recommends EU marketing authorization for ARS Pharma's epinephrine nasal spray EURneffy
--------------------------------------------------------------------------------

- CHMP adopted positive opinion for EURneffy (2 mg epinephrine nasal spray) for emergency anaphylaxis treatment.
- Indicated for adults and children ≥30 kg; EC decision expected within 67 days of June 27, 2024.
- EURneffy is a needle-free alternative to injectable epinephrine, potentially expanding treatment access.
- Corporate presentation updated for investor meetings; no financial guidance changes reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000119312524171204/0001193125-24-171204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000119312524171204/d860381d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-171204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer